M. Horyński

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn et al. · Gastroenterology · 2021 · 216 citations

Inflammation, Anti-inflammatory, Controlled Trial +5

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

Wolfgang Kruis, Gediminas Kiudelis, I Rácz et al. · Gut · 2008 · 201 citations · Full text

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

Wolfgang Kruis, Laimas Virginijus Jonaitis, Juris Pokrotnieks et al. · Alimentary Pharmacology & Therapeutics · 2010 · 79 citations

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber et al. · Gastroenterology · 2024 · 53 citations · Full text